Gene
AREG
AREG is a gene biomarker in the evidence tier "Cancer actionable (CGI)". This page lists evidence by type: Assay-provider ledger (24), Actionable biomarkers (1), Trial mentions (4), and 5 more evidence types, each linked to its source.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section (log scale)
4 sections measured, none recorded
Cancer actionable (CGI)
Evidence over time
Share of that year: what fraction of the trials and papers our biomarker dictionary matched in a year mention AREG. The denominator is documents that mention any gene, not every registered document, so improving the matcher moves both halves and never rewrites history. Gene named in free-text trial records. A mention, not a validated biomarker. Actionable-biomarker and target-disease-association evidence carries no date in our sources, so it is not on this chart. Publication mentions cover only papers cited by a registered clinical trial, not all of PubMed.
Trial mentions: plotted from 1990 to 2026, the years our matched corpus covers.
Publication mentions: plotted from 1990 to 2023, the years our matched corpus covers. Not plotted: 3 at the structurally incomplete recent edge.
AREG has 4 trial mentions across 3 years. That is too few to read as a trend, so the years are listed instead.
The yearly numbers
| Year | Trial mentions | Share of that year | Publication mentions | Share of that year |
|---|---|---|---|---|
| 2026 | 2 of 8,738 | 0.02% | not measured | |
| 2025 | 0 of 8,875 | 0.00% | not measured | |
| 2024 | 0 of 8,597 | 0.00% | not measured | |
| 2023 | 1 of 8,275 | 0.01% | 14 of 11,460 | 0.12% |
| 2022 | 0 of 8,285 | 0.00% | 10 of 13,598 | 0.07% |
| 2021 | 0 of 8,692 | 0.00% | 14 of 15,045 | 0.09% |
| 2020 | 0 of 7,640 | 0.00% | 19 of 14,459 | 0.13% |
| 2019 | 0 of 7,300 | 0.00% | 11 of 12,159 | 0.09% |
| 2018 | 0 of 6,927 | 0.00% | 9 of 11,854 | 0.08% |
| 2017 | 0 of 6,558 | 0.00% | 11 of 11,595 | 0.09% |
Showing 10 of 37 years.
Assay-provider ledger (24)
Shown in this order: most recent publication first.
| Company | Provider class | Validation | Papers | Most recent publication |
|---|---|---|---|---|
| BioTek Instruments | Reagent supplier | Clinical validation | 1 | March 13, 2026 |
| Elabscience Biotechnology | Reagent supplier | Clinical validation | 1 | March 13, 2026 |
| Shanghai SunRed Biological Technology Co. | Reagent supplier | Clinical validation | 1 | March 13, 2026 |
| Guang Zhou LBP Medicine Science & Technology Co., Ltd. | Diagnostic provider | Clinical validationAnalytical validation | 1 | March 26, 2024 |
| LC-Bio Technology Co., Ltd. | Reagent supplier | Clinical validationAnalytical validation | 1 | March 26, 2024 |
Showing 5 of 24 assay-provider companies.
Actionable biomarkers (1)
Shown in this order: fixed catalogue order, not ranked.
| Alteration | Drug | Response | Disease | Source |
|---|---|---|---|---|
| AREG amplification | Egfr Mab Inhibitors | response-associated | colorectal adenocarcinoma | Cancer Genome Interpreter |
Trial mentions (4)
Shown in this order: fixed catalogue order, not by date.
| Trial | Source |
|---|---|
| NCT07407543 | Trial eligibility (AACT) |
| NCT07094893 | Trial eligibility (AACT) |
| NCT05123040 | Trial eligibility (AACT) |
| NCT02525029 | Trial eligibility (AACT) |
Target-disease associations (254)
Shown in this order: fixed catalogue order, not ranked.
| Disease | Therapeutic area | Source |
|---|---|---|
| Adult-onset autosomal recessive sideroblastic anemia | genetic, familial or congenital disease | Mouse knockout (IMPC) |
| Alzheimer disease | nervous system disease | Literature (Europe PMC) |
| Arrhythmia | phenotype | Literature (Europe PMC) |
| Autoimmunity | phenotype | Literature (Europe PMC) |
| Bartsocas-Papas syndrome 1 | genetic, familial or congenital disease | Literature (Europe PMC) |
Showing 5 of 254 associations.
Vendor sourcing (13)
Shown in this order: alphabetical by organization.
| Organization | Role | Tier | Evidence | Citation |
|---|---|---|---|---|
| Ambry Genetics (United States) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | The c.469G>A (p.G157R) alteration is located in exon 3 (coding exon 3) of the AREG gene. This alteration results from a G to A substitution at nucleotide pos... | View ClinVar record SCV003605652.2 |
| Gruppo Oncologico del Nord Ovest | Trial sponsor | Named in trial inclusion criteriaTrial eligibility criteria | for Registration: * Age ≥18 years * Biopsy-confirmed adenocarcinoma of the colon with a right primary tumour location * aCRC defined as either M1 or locally... | View trial NCT07094893 |
| Gruppo Oncologico del Nord Ovest | Trial sponsor | Mentioned in trial textTrial free-text mention | AREG | View trial NCT07094893 |
| Labcorp Holdings Inc. | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | No supporting text recorded; see the citation. | View ClinVar record SCV001121456.1 |
| Masonic Cancer Center | Trial sponsor | Named in trial inclusion criteriaTrial eligibility criteria | : HCT recipients over 12 years of age within the first 7 days of initial treatment of high-risk aGVHD, defined as: * Newly diagnosed Minnesota high-risk aG... | View trial NCT05123040 |
Showing 5 of 13 sourcing records.
Trial-cited literature (160)
Shown in this order: newest first, then most cited.
| Publication | Journal | Year | Citations |
|---|---|---|---|
| Fecal microbiota transplantation promotes type 2 mucosal immune responses with colonic epithelium proliferation in patients with recurrent Clostridioides difficile. | JCI insight | 2026 | 5 |
| Dupilumab Dampens Mucosal Type 2 Response During Acetylsalicylic Acid Challenge in N-ERD Patients. | Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology | 2025 | 0 |
| Distinct baseline immune characteristics associated with responses to conjugated and unconjugated pneumococcal polysaccharide vaccines in older adults. | Nature immunology | 2024 | 33 |
| Autologous regulatory T-cell transfer in refractory ulcerative colitis with concomitant primary sclerosing cholangitis. | Gut | 2023 | 83 |
| Overview of Trop-2 in Cancer: From Pre-Clinical Studies to Future Directions in Clinical Settings. | Cancers | 2023 | 52 |
Showing 5 of 160 papers.
Literature-extracted relations (29)
Shown in this order: chemicals, then diseases.
| Related entity | Kind | Source relation label | Paper | Year |
|---|---|---|---|---|
| AFATINIB | Chemical | associate |
Combining gene expression analysis of gastric cancer cell lines and tumor specimens to identify biomarkers for anti-HER therapies-the role of HAS2, SHB and HBEGF. | 2022 |
| CETUXIMAB | Chemical | associate |
Combining gene expression analysis of gastric cancer cell lines and tumor specimens to identify biomarkers for anti-HER therapies-the role of HAS2, SHB and HBEGF. | 2022 |
| Progesterone | Chemical | associate |
The direct and indirect effects of kisspeptin-54 on granulosa lutein cell function. | 2018 |
| Progesterone | Chemical | positive_correlate |
Progesterone-Based Therapy Protects Against Influenza by Promoting Lung Repair and Recovery in Females. | 2016 |
| PANITUMUMAB | Chemical | associate |
Combined Epiregulin and Amphiregulin Expression Levels as a Predictive Biomarker for Panitumumab Therapy Benefit or Lack of Benefit in Patients With RAS Wild-Type Advanced Colorectal Cancer. | 2016 |
Showing 5 of 29 relation assertions.
Organizations publishing (178)
Shown in this order: most papers first.
| Organization | Type | Papers | Years |
|---|---|---|---|
| Memorial Sloan Kettering Cancer Center | Hospital | 6 | 1993 to 2017 |
| Government of the United States of America | Government | 5 | 2010 to 2020 |
| University of Minnesota System | Academic | 5 | 2011 to 2023 |
| Dana-Farber Cancer Institute | Other | 4 | 2015 to 2020 |
| Harvard Medical School | Academic | 4 | 2017 to 2021 |
Showing 5 of 178 organizations.
Where AREG appears
- animal disease
- biological_process
- cancer or benign tumor
- cardiovascular disease
- disorder of visual system
- endocrine system disease
- gastrointestinal disease
- genetic, familial or congenital disease
- hematologic disease
- immune system disease
- infectious disease
- injury, poisoning or other complication
- integumentary system disease
- measurement
- musculoskeletal or connective tissue disease
- nervous system disease
- phenotype
- reproductive system or breast disease
- respiratory or thoracic disease
- urinary system disease
249 diseases touched.
Not on this page
Checked, with nothing recorded for this biomarker: fda companion diagnostic assertions, fda biomarker qualification projects, protein variant mentions, and human sample screening reference.